Alzamend Neuro and Mass General Launch Phase II Trial for AL001 in Alzheimer’s Disease
Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, has announced a partnership with…
Mettler-Toledo Reports Q2 2024 Results
Mettler-Toledo International Inc. (NYSE: MTD) has released its financial results for the second quarter of 2024. Key highlights include: Second Quarter Highlights Management Commentary Patrick Kaltenbach, President and CEO, commented,…
Amylyx Pharmaceuticals Gets EU Orphan Drug Status for AMX0035 in Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has announced that the European Commission has granted Orphan Drug Designation to AMX0035, its proprietary fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO), for…
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(C)(4)
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company specializing in innovative treatments for neurological diseases, has announced the grant of inducement awards to two new employees. The Compensation Committee…
DocGo Extends $4 Million 911 Basic Life Support Contract with Atlantic City
DocGo Inc. (Nasdaq: DCGO), a leader in technology-enabled mobile health services, has announced that its subsidiary, Exceptional Medical Transportation, has been granted a one-year, $4 million contract extension. This extension…
Agilent’s MAGE-A4 IHC 1F9 PharmDx Approved by FDA for New TCR T-Cell Therapy
Agilent Technologies Inc. (NYSE: A) has announced FDA approval for its MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may qualify for…
VBI Vaccines Updates Restructuring Efforts
VBI Vaccines Inc. (Nasdaq: VBIV) has provided an update on its restructuring proceedings, initially announced on July 30, 2024. U.S. Chapter 15 Filing:On August 2, 2024, the U.S. Bankruptcy Court…
Owens & Minor Reports Q2 2024 Financial Results
Owens & Minor, Inc. (NYSE: OMI) Announces Second Quarter Financial Results for 2024 Owens & Minor, Inc. (NYSE: OMI) has released its financial results for the second quarter ending June…
BostonGene Partners with Takeda for AI-Driven Immunotherapy Evaluation
BostonGene, a leader in AI-driven molecular and immune profiling solutions, has announced a new research collaboration with Takeda focused on immuno-oncology. This partnership aims to enhance clinical solutions and patient…
Twist Bioscience Reports Q3 2024 Financial Results
Twist Bioscience Corporation (NASDAQ: TWST), known for its high-quality synthetic DNA via its silicon platform, has reported its financial results and business highlights for the third quarter of fiscal 2024,…
Adaptimmune’s TECELRA® Gets FDA Accelerated Approval as First Engineered Cell Therapy for Solid Tumors
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced that the U.S. FDA has granted accelerated approval for TECELRA® (afamitresgene autoleucel) as the first engineered cell therapy for treating solid tumors. This…
VSee Health and Ava Robotics Team Up for ICU Telepresence Solutions
VSee Health, Inc. (Nasdaq: VSEE), known for its telehealth services that optimize workflows and improve patient care, has partnered with Ava Robotics, a leader in intelligent workplace robots. Together, they…